Medosome Biotec, LLC
Alachua, FL · Biotech · Private
Engineered probiotics (Lactobacillus) platform for oral delivery of peptide and protein therapeutics
- Grants
- $16M
- 24 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Rapid Haplotyping procedure for determining the response of patients to DCA | $122,439 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery of Oligodendrocyte Stimulators | $217,801 | |
| Federal grant | Department of Health and Human Services · Phase I · A method for accurate and sensitive detection of HIV drug-resistant minority variants | $253,244 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapies for inherited muscle diseases | $224,463 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Optimized AAV Serotype Vectors for Human Gene Therapy | $294,094 | |
| Federal grant | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $224,978 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of CaSR nutrient therapy for childhood diarrhea | $223,899 | |
| Federal grant | Department of Health and Human Services · Phase I · Next generation quantitative HCV drug resistance assay | $232,433 | |
| Federal grant | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $793,897 | |
| Federal grant | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $695,065 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of White Matter Injury in Premature Infants | $223,899 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Novel Therapeutic for Hyperthyroidism | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7 | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of White Matter Injury in Premature Infants | $1,693,867 | |
| Federal grant | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $2,978,087 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of White Matter Injury in Premature Infants | $700,593 | |
| Federal grant | Department of Health and Human Services · Phase II · Next generation quantitative HCV drug resistance assay | $834,451 | |
| Federal grant | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $992,757 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Next generation quantitative HCV drug resistance assay | $776,646 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Personalized dosing of dichloroacetate for the treatment of rare and common diseases | $985,330 | |
| Federal grant | Department of Health and Human Services · Phase II · A method for accurate and sensitive detection of HIV drug-resistant minority variants | $999,999 | |
| Federal grant | Department of Health and Human Services · Phase II · A method for accurate and sensitive detection of HIV drug-resistant minority variants | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering next generation probiotics for delivery of therapeutics | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Metabolism and Mitochondrial Energetics Therapy for Septic Shock | $350,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2190 | GREENSTONE BIOSCIENCES, INC. | — | $10M |
| 2191 | SILCSBIO LLC | — | — |
| 2192 | Hemab Therapeutics | — | — |
| 2193 | Medosome Biotec, LLC | — | — |
| 2194 | ADVERTENT BIOTHERAPEUTICS, INC. | — | — |
| 2195 | Avometric | — | — |
| 2196 | OVATION SCIENCE INC. | — | $150K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.